208 related articles for article (PubMed ID: 32308206)
1. Life-threatening laryngeal attacks in hereditary angioedema patients.
Piotrowicz-Wójcik K; Porebski G
Otolaryngol Pol; 2020 Mar; 74(2):1-5. PubMed ID: 32308206
[TBL] [Abstract][Full Text] [Related]
2. Hereditary angioedema: management of laryngeal attacks.
Christiansen SC; Zuraw BL
Am J Rhinol Allergy; 2011; 25(6):379-82. PubMed ID: 22185739
[TBL] [Abstract][Full Text] [Related]
3. Pathophysiology of hereditary angioedema.
Zuraw BL; Christiansen SC
Am J Rhinol Allergy; 2011; 25(6):373-8. PubMed ID: 22185738
[TBL] [Abstract][Full Text] [Related]
4. Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.
Longhurst HJ; Zanichelli A; Caballero T; Bouillet L; Aberer W; Maurer M; Fain O; Fabien V; Andresen I;
Clin Exp Immunol; 2017 Apr; 188(1):148-153. PubMed ID: 27936514
[TBL] [Abstract][Full Text] [Related]
5. The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks.
Longhurst HJ; Aberer W; Bouillet L; Caballero T; Maurer M; Fabien V; Zanichelli A;
Eur J Emerg Med; 2016 Jun; 23(3):224-7. PubMed ID: 27116379
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic management of hereditary angioedema due to C1 inhibitor deficiency.
Zanichelli A; Mansi M; Periti G; Cicardi M
Expert Rev Clin Immunol; 2013 May; 9(5):477-88. PubMed ID: 23634741
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy.
Hakl R; Kuklínek P; Krčmová I; Králíčková P; Freiberger T; Janků P; Vlková M; Litzman J
J Clin Immunol; 2018 Oct; 38(7):810-815. PubMed ID: 30280305
[TBL] [Abstract][Full Text] [Related]
8. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant.
Bouillet L; Boccon-Gibod I; Launay D; Gompel A; Kanny G; Fabien V; Fain O;
Immun Inflamm Dis; 2017 Mar; 5(1):29-36. PubMed ID: 28250922
[TBL] [Abstract][Full Text] [Related]
9. Content validity of visual analog scales to assess symptom severity of acute angioedema attacks in adults with hereditary angioedema: an interview study.
McMillan CV; Speight J; Relan A; Bellizzi L; Haase G; Cicardi M
Patient; 2012; 5(2):113-26. PubMed ID: 22462765
[TBL] [Abstract][Full Text] [Related]
10. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.
Malbrán A; Riedl M; Ritchie B; Smith WB; Yang W; Banerji A; Hébert J; Gleich GJ; Hurewitz D; Jacobson KW; Bernstein JA; Khan DA; Kirkpatrick CH; Resnick D; Li H; Fernández Romero DS; Lumry W
Clin Exp Immunol; 2014 Aug; 177(2):544-53. PubMed ID: 24749847
[TBL] [Abstract][Full Text] [Related]
11. Icatibant for hereditary angioedema.
Gras J
Drugs Today (Barc); 2009 Dec; 45(12):855-64. PubMed ID: 20135020
[TBL] [Abstract][Full Text] [Related]
12. Management and prevention of hereditary angioedema attacks.
Lumry WR
Am J Manag Care; 2013 Jun; 19(7 Suppl):s111-8. PubMed ID: 23844783
[TBL] [Abstract][Full Text] [Related]
13. Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.
Lumry WR; Li HH; Levy RJ; Potter PC; Farkas H; Moldovan D; Riedl M; Li H; Craig T; Bloom BJ; Reshef A
Ann Allergy Asthma Immunol; 2011 Dec; 107(6):529-37. PubMed ID: 22123383
[TBL] [Abstract][Full Text] [Related]
14. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.
Lumry WR; Farkas H; Moldovan D; Toubi E; Baptista J; Craig T; Riedl M
Int Arch Allergy Immunol; 2015; 168(1):44-55. PubMed ID: 26556097
[TBL] [Abstract][Full Text] [Related]
15. Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study.
Campos RA; Valle SO; França AT; Cordeiro E; Serpa FS; Mello YF; Malheiros T; Toledo E; Mansour E; Fusaro G; Grumach AS
Sao Paulo Med J; 2014; 132(5):261-5. PubMed ID: 25054967
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility.
Otani IM; Lumry WR; Hurwitz S; Li HH; Craig TJ; Holtzman NS; Iandoli MI; Tucker J; Riedl MA; Zuraw BL; Banerji A
J Allergy Clin Immunol Pract; 2017; 5(2):442-447.e1. PubMed ID: 27818136
[TBL] [Abstract][Full Text] [Related]
17. Hereditary angioedema: a case of near fatal laryngeal swelling in a 41-year-old woman.
Lumry WR
Allergy Asthma Proc; 2011; 32 Suppl 1():13-15. PubMed ID: 22195756
[TBL] [Abstract][Full Text] [Related]
18. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.
Farkas H; Reshef A; Aberer W; Caballero T; McCarthy L; Hao J; Nothaft W; Schranz J; Bernstein JA; Li HH
J Allergy Clin Immunol Pract; 2017; 5(6):1671-1678.e2. PubMed ID: 28601641
[TBL] [Abstract][Full Text] [Related]
19. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.
Baş M; Greve J; Hoffmann TK; Reshef A; Aberer W; Maurer M; Kivity S; Farkas H; Floccard B; Arcoleo F; Martin L; Sitkauskiene B; Bouillet L; Schmid-Grendelmeier P; Li H; Zanichelli A
Allergy; 2013 Nov; 68(11):1452-9. PubMed ID: 24111645
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 and hereditary angioedema: Incidence, outcomes, and mechanistic implications.
Veronez CL; Christiansen SC; Smith TD; Riedl MA; Zuraw BL
Allergy Asthma Proc; 2021 Nov; 42(6):506-514. PubMed ID: 34871158
[No Abstract] [Full Text] [Related]
[Next] [New Search]
